

## [Pembrolizumab](#)

Statut de médicament essentiel

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.3. Immunomodulators](#)

Codes ATC: [L01FF02](#)

Indication

Melanoma of skin Code ICD11: [2C30](#)

INN

Pembrolizumab

Type de médicament

Biological agent

Type de liste

Liste de base

Additional notes

\*including quality-assured biosimilars

Formulations

**Parenteral > General injections > IV: 25 mg per mL in 4 mL vial**

Historique des statuts LME

Ajouté pour la première fois en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

[nivolumab](#) (Codes ATC: [L01FF01](#))

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Renseignements sur le brevet

Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Lire la suite [sur les brevets.](#)

Balises

Cancer

Wikipédia

[Pembrolizumab](#)

[DrugBank](#)

[Pembrolizumab](#)

Résumé des preuves et recommandation du comité d'experts

With the 2025 recommendation to list pembrolizumab for first-line monotherapy of metastatic non-small cell lung cancer with high PD-L1 expression ( $\geq 50\%$ ), first-line monotherapy for deficient mismatch repair/microsatellite instability-high metastatic colorectal cancer, and in combination with platinum-based chemotherapy, as first-line treatment of metastatic cervical cancer with PD-L1 expression  $\geq 1\%$ , the Expert Committee recommended changing the current square box listing of nivolumab as the class representative and pembrolizumab as the specified therapeutic alternative for metastatic melanoma, to make pembrolizumab the class representative with nivolumab as the specified therapeutic alternative. This is intended to signal to countries the possibility of aggregating procurement of a single molecule, pembrolizumab, for multiple cancer indications, which can influence price negotiations with manufacturers. Limiting procurement fragmentation by focusing on a select few immune checkpoint inhibitors is likely to facilitate central purchasing through competitive tendering and better competition from pembrolizumab biosimilars, thereby increasing access.